Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Monday released topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the ...

Before GLP-1 agonists became the blockbuster obesity drugs many people know and use today, Rhythm Pharmaceuticals was researching molecules that take a similar approach but for a different target. The ...

Please provide your email address to receive an email when new articles are posted on . Setmelanotide was linked to reduction in BMI at 52 weeks compared with placebo for patients with acquired ...

Rhythm Pharmaceuticals' Q2 revenue rose to $29.1 million, driven by global sales of Imcivree, its treatment for rare genetic obesity disorders. The company's cash and investments totaled $319 million ...

Rhythm Pharmaceuticals Inc. is set to report fourth-quarter results Thursday before the market opens, delivering a crucial financial snapshot just weeks before a regulatory decision that could ...

April 7 (Reuters) - Rhythm Pharmaceuticals (RYTM.O), opens new tab said on Monday its drug Imcivree notably reduced weight in patients with a rare obesity disorder caused by damage to the brain, ...

Detailed price information for Palatin Technologies Inc (PTN-A) from The Globe and Mail including charting and trades.

Palatin Technologies (NYSE:PTN) has been gaining attention in recent months as investors look beyond GLP-1 drugs toward more specialized obesity indications. While most of the obesity market focuses ...

Rhythm Pharmaceuticals is pursuing approval for its rare obesity disorder drug Imcivree in acquired hypothalamic obesity after it showed a 19.8% weight loss in a Phase III trial. The Boston-based ...

Breakthrough MRI scans reveal hidden hypothalamic changes in young women, shedding light on the biological roots of anorexia and obesity, and paving the way for targeted treatments. Study: Unraveling ...

Metabolic syndrome (MetS) is a multifaceted disorder that impacts approximately 20–25% of the global population. This syndrome encompasses a range of conditions, including obesity, type 2 diabetes ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive weight loss effects IND-enabling ...